{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:23Z","timestamp":1792787843669,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"LivaNova Belgium"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Depressive illness is associated with significant adverse consequences for patients and their families, and for society. Clinical challenges are encountered in the management of patients suffering from depression whether they are designated difficult-to-treat or treatment-resistant. Prospective serial depression treatment trials have shown that less than 40% of patients with major depressive disorder remit with an initial pharmacotherapy trial, and a progressively smaller proportion of patients remit with each subsequent trial. For patients who suffer from difficult-to-treat depression (DTD), treatments should focus on patient-centred symptom control, patient functioning, and improving patient quality of life. Among the treatment options for patients with DTD is Vagus Nerve Stimulation (VNS) Therapy. VNS Therapy involves intermittent electrical stimulation of the left cervical vagus nerve and has been shown to be efficacious for long-term management of patients with DTD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RESTORE-LIFE is a prospective, observational, multi-site, global post-market study intended to assess short-, mid-, and long-term effectiveness and efficiency outcomes in a \u2018real-world\u2019 setting among patients with DTD treated with adjunctive VNS Therapy. A minimum of 500 patients will be implanted with a VNS Therapy System at up to 80 global sites. Eligible patients will participate in a baseline visit between 1 and 6\u2009weeks before device implant and will be followed for a minimum of 36\u2009months and a maximum of 60\u2009months. The diagnosis of depression and comorbid disorders will be determined using the Mini-International Neuropsychiatric Interview (MINI). The primary endpoint is response rate, defined as a decrease of \u226550% in Montgomery \u00c5sberg Depression Rating Scale (MADRS) total score from baseline to 12\u2009months post-implant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>A standardized approach in the management of DTD may not be appropriate for the treatment of such a complex heterogenous patient population. This study has been designed to evaluate whether VNS Therapy meaningfully improves and sustains clinical and depressive symptom outcomes in patients with DTD. This study will investigate the durability of VNS response in DTD and utility of VNS for long-term disease management of DTD. In addition, the study results will potentially clarify clinical, functional, and health economic questions in a real-world patient population with DTD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03320304\">NCT03320304.<\/jats:ext-link>\n                      Registered 25 October 2017\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12888-020-02869-6","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T08:03:11Z","timestamp":1601366591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Vagus nerve stimulation as adjunctive therapy in patients with difficult-to-treat depression (RESTORE-LIFE): study protocol design and rationale of a real-world post-market study"],"prefix":"10.1186","volume":"20","author":[{"given":"Allan H.","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario F.","family":"Juruena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske","family":"De Zwaef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Demyttenaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"key":"2869_CR1","unstructured":"Depression and Other Common Mental Disorders: Global Health Estimates. World Health Organization, Geneva, Switzerland. 2017. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/254610\/WHO-MSD-MER-2017.2-eng.pdf;sequence=1. Accessed 19 Feb 2020."},{"key":"2869_CR2","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","volume":"392","author":"DALYs GBD, Collaborators H.","year":"2018","unstructured":"DALYs GBD, Collaborators H. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392:1859\u2013922. https:\/\/doi.org\/10.1016\/S0140-6736(18)32335-3.","journal-title":"Lancet"},{"key":"2869_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psc.2011.11.005","volume":"35","author":"RC Kessler","year":"2012","unstructured":"Kessler RC. The costs of depression. Psychiatr Clin North Am. 2012;35:1\u201314. https:\/\/doi.org\/10.1016\/j.psc.2011.11.005.","journal-title":"Psychiatr Clin North Am"},{"key":"2869_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3111\/13696998.2012.724745","volume":"16","author":"RL Feldman","year":"2013","unstructured":"Feldman RL, Dunner DL, Muller JS, Stone DA. Medicare patient experience with vagus nerve stimulation for treatment-resistant depression. J Med Econ. 2013;16:62\u201374. https:\/\/doi.org\/10.3111\/13696998.2012.724745.","journal-title":"J Med Econ"},{"key":"2869_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jad.2018.06.030","volume":"238","author":"J Reutfors","year":"2018","unstructured":"Reutfors J, Andersson TM, Brenner P, Brandt L, DiBernardo A, Li G, et al. Mortality in treatment-resistant unipolar depression: a register-based cohort study in Sweden. J Affect Disord. 2018;238:674\u20139. https:\/\/doi.org\/10.1016\/j.jad.2018.06.030.","journal-title":"J Affect Disord"},{"key":"2869_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/070674370705200108","volume":"52","author":"MT Berlim","year":"2007","unstructured":"Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: a review of current concepts and methods. Can J Psychiatr. 2007;52:46\u201354. https:\/\/doi.org\/10.1177\/070674370705200108.","journal-title":"Can J Psychiatr"},{"key":"2869_CR7","first-page":"222","volume":"26","author":"K Trevino","year":"2014","unstructured":"Trevino K, McClintock SM, McDonald Fischer N, Vora A, Husain MM. Defining treatment-resistant depression: a comprehensive review of the literature. Ann Clin Psychiatry. 2014;26:222\u201332.","journal-title":"Ann Clin Psychiatry"},{"key":"2869_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","volume":"163","author":"MH Trivedi","year":"2006","unstructured":"Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28\u201340. https:\/\/doi.org\/10.1176\/appi.ajp.163.1.28.","journal-title":"Am J Psychiatry"},{"key":"2869_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.2165\/00023210-200923080-00001","volume":"23","author":"AJ Rush","year":"2009","unstructured":"Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23:627\u201347. https:\/\/doi.org\/10.2165\/00023210-200923080-00001.","journal-title":"CNS Drugs"},{"key":"2869_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1176\/appi.ajp.163.7.1161","volume":"163","author":"M Fava","year":"2006","unstructured":"Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161\u201372. https:\/\/doi.org\/10.1176\/appi.ajp.163.7.1161.","journal-title":"Am J Psychiatry"},{"key":"2869_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(12)61552-9","volume":"381","author":"N Wiles","year":"2013","unstructured":"Wiles N, Thomas L, Abel A, Ridgway N, Turner N, Campbell J, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet. 2013;381:375\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(12)61552-9.","journal-title":"Lancet"},{"key":"2869_CR12","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1176\/appi.ajp.2012.12050648","volume":"169","author":"CH Kellner","year":"2012","unstructured":"Kellner CH, Greenberg RM, Murrough JW, Bryson EO, Briggs MC, Pasculli RM. ECT in treatment-resistant depression. Am J Psychiatry. 2012;169:1238\u201344. https:\/\/doi.org\/10.1176\/appi.ajp.2012.12050648.","journal-title":"Am J Psychiatry"},{"key":"2869_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3949\/ccjm.75.1.57","volume":"75","author":"BN Gaynes","year":"2008","unstructured":"Gaynes BN, Rush AJ, Trivedi MH, Wisniewski SR, Spencer D, Fava M. The STAR*D study: treating depression in the real world. Cleve Clin J Med. 2008;75:57\u201366. https:\/\/doi.org\/10.3949\/ccjm.75.1.57.","journal-title":"Cleve Clin J Med"},{"key":"2869_CR14","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1176\/ajp.2006.163.9.1531","volume":"163","author":"PJ McGrath","year":"2006","unstructured":"McGrath PJ, Stewart JW, Fava M, Trivedi MH, Wisniewski SR, Nierenberg AA, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163:1531\u201341; quiz 1666. https:\/\/doi.org\/10.1176\/ajp.2006.163.9.1531.","journal-title":"Am J Psychiatry"},{"key":"2869_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.psc.2011.11.004","volume":"35","author":"GI Keitner","year":"2012","unstructured":"Keitner GI, Mansfield AK. Management of treatment-resistant depression. Psychiatr Clin North Am. 2012;35:249\u201365. https:\/\/doi.org\/10.1016\/j.psc.2011.11.004.","journal-title":"Psychiatr Clin North Am"},{"key":"2869_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0004867418808585","volume":"53","author":"AJ Rush","year":"2019","unstructured":"Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry. 2019;53:109\u201318. https:\/\/doi.org\/10.1177\/0004867418808585.","journal-title":"Aust N Z J Psychiatry"},{"key":"2869_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2165\/00019053-200422060-00003","volume":"22","author":"P Greenberg","year":"2004","unstructured":"Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22:363\u201373.","journal-title":"Pharmacoeconomics"},{"key":"2869_CR18","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1001\/jama.291.21.2581","volume":"291","author":"K Demyttenaere","year":"2004","unstructured":"Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization world mental health surveys. JAMA. 2004;291:2581\u201390. https:\/\/doi.org\/10.1001\/jama.291.21.2581.","journal-title":"JAMA"},{"key":"2869_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/09638237.2017.1417562","volume":"27","author":"P McCrone","year":"2018","unstructured":"McCrone P, Rost F, Koeser L, Koutoufa I, Stephanou S, Knapp M, et al. The economic cost of treatment-resistant depression in patients referred to a specialist service. J Ment Health. 2018;27:567\u201373. https:\/\/doi.org\/10.1080\/09638237.2017.1417562.","journal-title":"J Ment Health"},{"key":"2869_CR20","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","volume":"267","author":"RH McAllister-Williams","year":"2020","unstructured":"McAllister-Williams RH, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. J Affect Disord. 2020;267:264\u201382. https:\/\/doi.org\/10.1016\/j.jad.2020.02.023.","journal-title":"J Affect Disord"},{"key":"2869_CR21","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/wps.20677","volume":"18","author":"K Demyttenaere","year":"2019","unstructured":"Demyttenaere K. What is treatment resistance in psychiatry? A \u201cdifficult to treat\u201d concept. World Psychiatry. 2019;18:354\u20135. https:\/\/doi.org\/10.1002\/wps.20677.","journal-title":"World Psychiatry"},{"key":"2869_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.9758\/cpn.2014.12.2.83","volume":"12","author":"A Shah","year":"2014","unstructured":"Shah A, Carreno FR, Frazer A. Therapeutic modalities for treatment resistant depression: focus on vagal nerve stimulation and ketamine. Clin Psychopharmacol Neurosci. 2014;12:83\u201393. https:\/\/doi.org\/10.9758\/cpn.2014.12.2.83.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"2869_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.biopsych.2005.07.028","volume":"58","author":"MS George","year":"2005","unstructured":"George MS, Rush AJ, Marangell LB, Sackeim HA, Brannan SK, Davis SM, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58:364\u201373. https:\/\/doi.org\/10.1016\/j.biopsych.2005.07.028.","journal-title":"Biol Psychiatry"},{"key":"2869_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.biopsych.2005.05.025","volume":"58","author":"AJ Rush","year":"2005","unstructured":"Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58:347\u201354. https:\/\/doi.org\/10.1016\/j.biopsych.2005.05.025.","journal-title":"Biol Psychiatry"},{"key":"2869_CR25","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.biopsych.2005.05.024","volume":"58","author":"AJ Rush","year":"2005","unstructured":"Rush AJ, Sackeim HA, Marangell LB, George MS, Brannan SK, Davis SM, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355\u201363. https:\/\/doi.org\/10.1016\/j.biopsych.2005.05.024.","journal-title":"Biol Psychiatry"},{"key":"2869_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.brs.2012.09.013","volume":"6","author":"ST Aaronson","year":"2013","unstructured":"Aaronson ST, Carpenter LL, Conway CR, Reimherr FW, Lisanby SH, Schwartz TL, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul. 2013;6:631\u201340. https:\/\/doi.org\/10.1016\/j.brs.2012.09.013.","journal-title":"Brain Stimul"},{"key":"2869_CR27","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1176\/appi.ajp.2017.16010034","volume":"174","author":"ST Aaronson","year":"2017","unstructured":"Aaronson ST, Sears P, Ruvuna F, Bunker M, Conway CR, Dougherty DD, et al. A 5-year observational study of patients with treatment-resistant depression treated with Vagus nerve stimulation or treatment as usual: comparison of response, remission, and Suicidality. Am J Psychiatry. 2017;174:640\u20138. https:\/\/doi.org\/10.1176\/appi.ajp.2017.16010034.","journal-title":"Am J Psychiatry"},{"key":"2869_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/MDER.S41017","volume":"6","author":"SM Berry","year":"2013","unstructured":"Berry SM, Broglio K, Bunker M, Jayewardene A, Olin B, Rush AJ. A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Med Devices (Auckl). 2013;6:17\u201335. https:\/\/doi.org\/10.2147\/MDER.S41017.","journal-title":"Med Devices (Auckl)"},{"key":"2869_CR29","doi-asserted-by":"publisher","first-page":"e48002","DOI":"10.1371\/journal.pone.0048002","volume":"7","author":"B Olin","year":"2012","unstructured":"Olin B, Jayewardene AK, Bunker M, Moreno F. Mortality and suicide risk in treatment-resistant depression: an observational study of the long-term impact of intervention. Plos One. 2012;7:e48002. https:\/\/doi.org\/10.1371\/journal.pone.0048002.","journal-title":"Plos One"},{"key":"2869_CR30","doi-asserted-by":"publisher","unstructured":"Conway CR, Kumar A, Xiong W, Bunker M, Aaronson ST, Rush AJ. Chronic Vagus nerve stimulation significantly improves quality of life in treatment-resistant major depression. J Clin Psychiatry. 2018;79. https:\/\/doi.org\/10.4088\/JCP.18m12178.","DOI":"10.4088\/JCP.18m12178"},{"key":"2869_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/YCT.0000000000000502","volume":"34","author":"V Desbeaumes Jodoin","year":"2018","unstructured":"Desbeaumes Jodoin V, Richer F, Miron JP, Fournier-Gosselin MP, Lesperance P. Long-term sustained cognitive benefits of Vagus nerve stimulation in refractory depression. J ECT. 2018;34:283\u201390. https:\/\/doi.org\/10.1097\/YCT.0000000000000502.","journal-title":"J ECT"},{"key":"2869_CR32","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.psc.2018.04.005","volume":"41","author":"CR Conway","year":"2018","unstructured":"Conway CR, Xiong W. The mechanism of action of Vagus nerve stimulation in treatment-resistant depression: current conceptualizations. Psychiatr Clin North Am. 2018;41:395\u2013407. https:\/\/doi.org\/10.1016\/j.psc.2018.04.005.","journal-title":"Psychiatr Clin North Am"},{"key":"2869_CR33","doi-asserted-by":"crossref","unstructured":"Aaronson ST, Kutzer DJ. Vagus nerve stimulation in patients requiring maintenance therapy after response to electroconvulsive therapy. Poster presented at the 30th European College of Neuropsychopharmacology (ECNP) congress, Paris, France; September 2017. In.","DOI":"10.26226\/morressier.5971be83d462b80290b5307b"},{"issue":"Suppl 20","key":"2869_CR34","first-page":"22","volume":"59","author":"DV Sheehan","year":"1998","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22\u201333 quiz 34\u201357.","journal-title":"J Clin Psychiatry"},{"key":"2869_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/2194-7511-1-21","volume":"1","author":"T Hergueta","year":"2013","unstructured":"Hergueta T, Weiller E. Evaluating depressive symptoms in hypomanic and manic episodes using a structured diagnostic tool: validation of a new Mini International Neuropsychiatric Interview (M.I.N.I.) module for the DSM-5 \u2018With Mixed Features\u2019 specifier. Int J Bipolar Disord. 2013;1:21. https:\/\/doi.org\/10.1186\/2194-7511-1-21.","journal-title":"Int J Bipolar Disord"},{"key":"2869_CR36","unstructured":"Diagnostic and statistical manual of mental disorders (5th edition), 2013. American Psychiatric Association, Washington."},{"key":"2869_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jpsychires.2019.03.021","volume":"113","author":"HA Sackeim","year":"2019","unstructured":"Sackeim HA, Aaronson ST, Bunker MT, Conway CR, Demitrack MA, George MS, et al. The assessment of resistance to antidepressant treatment: rationale for the antidepressant treatment history form: short form (ATHF-SF). J Psychiatr Res. 2019;113:125\u201336. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.03.021.","journal-title":"J Psychiatr Res"},{"key":"2869_CR38","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1046\/j.1528-1157.2001.0420081017.x","volume":"42","author":"CM DeGiorgio","year":"2001","unstructured":"DeGiorgio CM, Thompson J, Lewis P, Arrambide S, Naritoku D, Handforth A, et al. Vagus nerve stimulation: analysis of device parameters in 154 patients during the long-term XE5 study. Epilepsia. 2001;42:1017\u201320. https:\/\/doi.org\/10.1046\/j.1528-1157.2001.0420081017.x.","journal-title":"Epilepsia"},{"key":"2869_CR39","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/00004850-200211000-00003","volume":"17","author":"A Khan","year":"2002","unstructured":"Khan A, Khan SR, Shankles EB, Polissar NL. Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the clinical global impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol. 2002;17:281\u20135. https:\/\/doi.org\/10.1097\/00004850-200211000-00003.","journal-title":"Int Clin Psychopharmacol"},{"key":"2869_CR40","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382\u20139. https:\/\/doi.org\/10.1192\/bjp.134.4.382.","journal-title":"Br J Psychiatry"},{"key":"2869_CR41","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","volume":"54","author":"AJ Rush","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54:573\u201383.","journal-title":"Biol Psychiatry"},{"key":"2869_CR42","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S0006-3223(96)00548-3","volume":"42","author":"EG Altman","year":"1997","unstructured":"Altman EG, Hedeker D, Peterson JL, Davis JM. The Altman self-rating mania scale. Biol Psychiatry. 1997;42:948\u201355. https:\/\/doi.org\/10.1016\/S0006-3223(96)00548-3.","journal-title":"Biol Psychiatry"},{"key":"2869_CR43","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1176\/appi.ajp.2016.16020176","volume":"173","author":"MK Jha","year":"2016","unstructured":"Jha MK, Minhajuddin A, Greer TL, Carmody T, Rush AJ, Trivedi MH. Early improvement in work productivity predicts future clinical course in depressed outpatients: findings from the CO-MED trial. Am J Psychiatry. 2016;173:1196\u2013204. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16020176.","journal-title":"Am J Psychiatry"},{"key":"2869_CR44","first-page":"321","volume":"29","author":"J Endicott","year":"1993","unstructured":"Endicott J, Nee J, Harrison W, Blumenthal R. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321\u20136.","journal-title":"Psychopharmacol Bull"},{"key":"2869_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"G EuroQol","year":"1990","unstructured":"EuroQol G. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208. https:\/\/doi.org\/10.1016\/0168-8510(90)90421-9.","journal-title":"Health Policy"},{"key":"2869_CR46","doi-asserted-by":"publisher","first-page":"873","DOI":"10.4088\/JCP.16m11329","volume":"78","author":"RS McIntyre","year":"2017","unstructured":"McIntyre RS, Best MW, Bowie CR, Carmona NE, Cha DS, Lee Y, et al. The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. J Clin Psychiatry. 2017;78:873\u201381. https:\/\/doi.org\/10.4088\/JCP.16m11329.","journal-title":"J Clin Psychiatry"},{"key":"2869_CR47","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MLR.0b013e318160d093","volume":"46","author":"B Lowe","year":"2008","unstructured":"Lowe B, Decker O, Muller S, Brahler E, Schellberg D, Herzog W, et al. Validation and standardization of the generalized anxiety disorder screener (GAD-7) in the general population. Med Care. 2008;46:266\u201374. https:\/\/doi.org\/10.1097\/MLR.0b013e318160d093.","journal-title":"Med Care"},{"key":"2869_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1017\/S1092852917000578","volume":"24","author":"K Demyttenaere","year":"2019","unstructured":"Demyttenaere K, Mortier P, Kiekens G, Bruffaerts R. Is there enough \u201cinterest in and pleasure in\u201d the concept of depression? The development of the Leuven affect and pleasure scale (LAPS). CNS Spectr. 2019;24:265\u201374. https:\/\/doi.org\/10.1017\/S1092852917000578.","journal-title":"CNS Spectr"},{"key":"2869_CR49","volume-title":"VNS Therapy\u00ae System Depression Physician\u2019s Manual, US Version. For Healthcare Professionals","author":"LivaNova","year":"2019","unstructured":"LivaNova. VNS Therapy\u00ae System Depression Physician\u2019s Manual, US Version. For Healthcare Professionals. London: LivaNova, PLC; 2019. Accessed 11 June 2020."},{"key":"2869_CR50","doi-asserted-by":"publisher","first-page":"106066","DOI":"10.1016\/j.cct.2020.106066","volume":"95","author":"CR Conway","year":"2020","unstructured":"Conway CR, Olin B, Aaronson ST, Sackeim HA, Bunker M, Kriedt C, et al. A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult to treat depression: a novel design for a novel treatment. Contemp Clin Trials. 2020;95:106066. https:\/\/doi.org\/10.1016\/j.cct.2020.106066.","journal-title":"Contemp Clin Trials"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02869-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-020-02869-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-020-02869-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T20:28:45Z","timestamp":1632860925000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-020-02869-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2869"],"URL":"https:\/\/doi.org\/10.1186\/s12888-020-02869-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The design of the study was approved by the \u201cEthische Commissie Onderzoek UZ\/KU Leuven\u201d or the Ethics Committee Research of the University Hospital of Leuven in Belgium (Registration Number S61554), the \u201cLondon - Riverside Research Ethics Committee\u201d for South London and Maudsley NHS Foundation Trust of The Maudsley Hospital in London \u2013 United Kingdom (Reference Number 18\/LO\/1001), and by the respective ethics committees of all participating centres. To protect the welfare of participants, the study will be approved by the ethics committees at each participating site prior to enrolment of the site\u2019s first patient. The study will be conducted according to the study protocol and in compliance with recognized international standards. Any important protocol modifications and amendments will be immediately communicated to all the participating centres. Prospective participants will receive an explanation of all aspects of the study that is relevant for the participant to make his or her decision, and all participants have to provide a signed informed consent before participating in the study. Participants who provide a signed informed consent but do not satisfy the inclusion criteria will be withdrawn from the study prior to implant and will be considered screen failures; and sites will maintain logs of screening and consenting participants. Participants are informed that they can withdraw their consent at any time without negative consequences for their future care. Participants will be asked if they want to provide a reason for withdrawal. Study physicians can decide to withdraw a participant from the study for urgent medical reasons.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AHY\u2019s independent research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London; the views expressed are those of AHY and not necessarily those of the NHS, the NIHR, or the Department of Health. AHY has received fees for lectures and advisory boards from AstraZeneca, Eli Lilly, Lundbeck, Sunovion, Servier, LivaNova, Janssen, Allegan, and Bionomics. AHY is a consultant to Johnson & Johnson and LivaNova. AHY has received honoraria for attending advisory boards and presenting talks at meetings organized by LivaNova.MFJ is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King\u2019s College London; has received speaker honorarium fees and honoraria for attending advisory boards from AstraZeneca, Lundbeck, LivaNova, Janssen, Libbs, Daiichi-Sankyo, and Bionomics; is a consultant to Lundbeck, Johnson & Johnson and LivaNova; and has received honoraria for presenting talks at meetings organized by LivaNova.RDZ is an employee and shareholder of LivaNova.KD has been involved in advisory boards and speaker bureaus with Boehringer Ingelheim, Johnson & Johnson, LivaNova, Lundbeck, Pfizer, and Servier.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"471"}}